ストックスクリーナーアプリを入手
38.27
1.49%
0.56
前日終値:
$37.71
開ける：
$37.65
24時間の取引高:
1.46M
Relative Volume:
1.35
時価総額：
$4.34B
収益：
$14.09M
当期純損益:
$-176.94M
株価収益率:
-17.80
EPS:
-2.15
ネットキャッシュフロー:
$-141.24M
1週間 パフォーマンス:
-0.21%
1か月 パフォーマンス:
+4.91%
6か月 パフォーマンス:
+106.75%
1年 パフォーマンス:
+90.21%
1日の値動き範囲:
$36.59
$38.62
1週間の範囲:
$36.59
$40.88
52週間の値動き範囲:
$14.06
$41.47
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
NAMS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
38.27 | 4.28B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 再開されました | H.C. Wainwright | Buy |
| 2025-08-25 | 開始されました | Wells Fargo | Overweight |
| 2025-07-17 | 開始されました | Goldman | Neutral |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2025-06-10 | 開始されました | Stifel | Buy |
| 2025-06-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-15 | 開始されました | TD Cowen | Buy |
| 2024-03-14 | 開始されました | Scotiabank | Sector Outperform |
| 2024-01-18 | 開始されました | Guggenheim | Buy |
| 2024-01-16 | 開始されました | Piper Sandler | Overweight |
| 2023-10-30 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Newamsterdam Pharma Company Nv (NAMS) 最新ニュース
What drives NewAmsterdam Pharma Company NV KH6 stock priceDebt-to-Equity Ratio Analysis & Get Ahead with Our Profit-Packed Picks - earlytimes.in
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock a top pick in earnings seasonSwing Trade & Safe Investment Capital Preservation Plans - newser.com
Can a trend reversal in NewAmsterdam Pharma Company N.V. Equity Warrant lead to recovery - newser.com
Technical analysis overview for NewAmsterdam Pharma Company N.V. Equity Warrant stockMarket Movers & Risk Controlled Stock Alerts - newser.com
Is NewAmsterdam Pharma Company N.V. stock a good choice for value investorsQuarterly Risk Review & Weekly Market Pulse Alerts - newser.com
Will NewAmsterdam Pharma Company N.V. stock maintain dividend yield - newser.com
Is NewAmsterdam Pharma Company N.V. (KH6) stock a fit for income portfoliosOil Prices & Long-Term Growth Stock Strategies - newser.com
How NewAmsterdam Pharma Company N.V. stock performs in high volatility marketsPortfolio Gains Report & Safe Entry Zone Identification - newser.com
What does recent volatility data suggest for NewAmsterdam Pharma Company N.V. Equity WarrantPortfolio Growth Summary & Technical Buy Zone Confirmation - newser.com
How NewAmsterdam Pharma Company N.V. (KH6) stock compares with tech leaders2025 Momentum Check & Risk Adjusted Swing Trade Ideas - newser.com
Visual analytics tools that track NewAmsterdam Pharma Company N.V. Equity Warrant performanceIndex Update & Weekly High Momentum Picks - newser.com
How NewAmsterdam Pharma Company N.V. Equity Warrant stock performs in stagflation2025 Biggest Moves & AI Forecast for Swing Trade Picks - newser.com
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock recover faster than marketJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
(NAMS) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock withstand economic slowdownJuly 2025 Action & Precise Swing Trade Entry Alerts - newser.com
Is NewAmsterdam Pharma Company N.V. (KH6) stock attractive post correction2025 Big Picture & Scalable Portfolio Growth Ideas - newser.com
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock maintain momentum in 2025 - newser.com
Published on: 2025-11-16 17:37:14 - newser.com
Advanced analytics toolkit walkthrough for NewAmsterdam Pharma Company N.V. Equity WarrantMarket Volume Report & Low Drawdown Momentum Trade Ideas - newser.com
NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating (NASDAQ:NAMS) - Seeking Alpha
Why NewAmsterdam Pharma Company N.V. stock is seen as undervaluedDollar Strength & AI Based Buy and Sell Signals - newser.com
Can NewAmsterdam Pharma Company N.V. (KH6) stock surprise markets with earningsPortfolio Risk Summary & Long-Term Safe Investment Plans - newser.com
Using data models to predict NewAmsterdam Pharma Company N.V. Equity Warrant stock movement2025 Technical Overview & Accurate Intraday Trade Tips - newser.com
Tools to assess NewAmsterdam Pharma Company N.V.’s risk profile2025 Dividend Review & Technical Confirmation Trade Alerts - newser.com
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock trading at a premium valuationJuly 2025 Recap & Technical Pattern Based Buy Signals - newser.com
Pattern recognition hints at NewAmsterdam Pharma Company N.V. upsideJuly 2025 Sector Moves & Low Volatility Stock Recommendations - newser.com
Is NewAmsterdam Pharma Company N.V. (KH6) stock undervalued by metricsPortfolio Update Summary & Community Consensus Trade Alerts - newser.com
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock bottoming outJuly 2025 Price Swings & Weekly Breakout Stock Alerts - newser.com
Is NewAmsterdam Pharma Company N.V. stock poised for growthTreasury Yields & Fast Entry High Yield Stock Tips - newser.com
How to escape a deep drawdown in NewAmsterdam Pharma Company N.V.Weekly Loss Report & Verified Momentum Watchlists - newser.com
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock benefit from commodity pricesQuarterly Portfolio Summary & Low Volatility Stock Recommendations - newser.com
Newamsterdam Pharma Company Nv (NAMS) 財務データ
収益
当期純利益
現金流量
EPS
1.38%
1.42%
大文字化:
|
ボリューム (24 時間):